NCT01535014已完成3 期
Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients
Materia Medica Holding17 个研究点 分布在 1 个国家目标入组 493 人开始时间: 2011年12月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 493
- 试验地点
- 17
- 主要终点
- Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment
研究概览
简要总结
The purpose of this study is:
- To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients.
- To assess clinical efficacy of Dietressa in the dose of 6 tablets daily within 24 weeks of therapy in reducing body weight in obese patients.
- To compare clinical efficacy of two dosage patterns for Dietressa (1 tablet 6 times daily and 2 tablets 3 times daily) within 24 weeks in treatment of obese patients.
详细描述
In general, patients will be observed during 24 weeks of trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient subjects with BMI 30,0-34,9 kg/m
- •Male or female subjects aged 18 to 65 inclusive.
- •Use of and compliance with contraception methods by patients of reproductive age, of both sexes.
- •Presence of the patient's information sheet (informed consent form) for participation in the clinical trial.
排除标准
- •Symptomatic (secondary) obesity:
- •with established genetic defect (including as a part of known genetic syndromes affecting multiple organs): Prader-Willi syndrome, Alstrom's syndrome, Laurence-Moon-Biedl syndrome, Dercum's syndrome etc.
- •cerebral (adiposogenital dystrophy, Babinski-Frohlich syndrome): brain tumors; dissemination of systemic lesions, infectious diseases; against mental diseases.
- •endocrine: hypothyroid; hypoovarial; pituitary-hypothalamic disorders; adrenopathy.
- •iatrogenic (caused by drug administration, namely, insulin, glucocorticosteroids, neuroleptics etc.).
- •Compliance with a diet prescribed and monitored by the doctor to reduce body weight within 6 months before enrollment.
- •Participation in the lifestyle modification program within 6 months before enrollment.
- •Patients who quit smoking within 6 months before enrollment, or intending to quit smoking during the period of participation in the trial, as well as intending to begin smoking during the trial.
- •Uncontrolled arterial hypertension (patients with 1-3 degree AH, receiving no adequate antihypertensive therapy).
- •Type 1 and 2 diabetes mellitus.
- •Edema syndrome with various etiology (chronic cardiac failure, nephrotic syndrome, hepatic cirrhosis).
- •Circulatory failure, IIА degree and above.
- •Decompensated cardiovascular disease, liver, kidney or gastrointestinal tract disease, metabolic, respiratory, endocrine, hematologic disease, peripheral vessel disease or another medical state. Oncological disease.
- •Diseases and states, which, in the investigator's opinion, may prevent the patient from participating in the trial.
- •Past history of bulimia / non-drug abepithymia.
- •Past history of any bariatric surgeries.
- •Lipoplasty underwent less then 1 year prior to screening visit, or cavitary surgery less then 6 months prior to screening visit.
- •Surgeries scheduled within 6 months.
- •Allergy to/intolerance of any of the drug components used during treatment.
- •Malabsorption syndrome, including congenial or acquired lactase or another disaccharidase insufficiency.
- •Administration of drugs specified as "Prohibited concomitant therapy", within 6 months before enrollment.
- •Pregnancy, breast-feeding, unwillingness to comply with contraception methods during the trial and within 30 days after completion of participation in the trial.
- •Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal incapacity or limited legal capacity.
- •Patients, who, in the investigator's opinion, will fail to observe the requirements during the trial or adhere to the studied drug administration procedure.
- •Participation in other clinical trials within 3 months before enrolment in this trial.
- •Presence of other factors, complicating the patient's participation in the trial (e.g., planned lengthy business and other trips).
- •A patient is a part of the center's research staff, taking a direct part in the trial, or an immediate family member of the investigator. Immediate family members are defined as spouses, parents, children or siblings, regardless of whether full blood or adopted.
- •The patient is employed with Scientific Production Firm Materia Medica Holding LLC, i.e. is the company's employee, part-time employee under contract, or appointed official in charge of the trial, or their immediate family.
研究组 & 干预措施
Dietressa (2 tablets 3 times daily) for 24 weeks
Experimental
Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
干预措施: Dietressa (Drug)
Dietressa (1 tablet 6 times daily) for 24 weeks
Experimental
Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
干预措施: Dietressa (Drug)
Placebo (2 tablets 3 times daily)
Placebo Comparator
Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
干预措施: Placebo (Drug)
Placebo (1 tablet 6 times daily)
Placebo Comparator
Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment
时间窗: assessed after 24 weeks of treatment
Average Body Weight Change After 24 Weeks of Treatment
时间窗: assessed after 24 weeks of treatment
Average Relative Change in Body Weight After 24 Weeks of Treatment
时间窗: assessed after 24 weeks of treatment
次要结局
- Percentage of Subjects With a Decrease in Body Weight by 5 or More Percent of Baseline Body Weight After 4, 8, 12, 16, 20 and 24 Weeks of Treatment(assessed after 4, 8, 12, 16, 20, and 24 weeks of treatment)
- Waist Hip Ratio After 4, 12 and 24 Weeks of Treatment(assessed after 4,12 and 24 weeks of treatment)
- Average Relative Weight Change After 4, 8, 12, 16, 20 and 24 Weeks of Treatment(assessed after 4, 8, 12, 16, 20 and 24 weeks of treatment)
- Change in the Quality of Life According to the Data of SF-36 Health Status Survey Questionnaire (SF-36) After 4, 12 and 24 Weeks of Treatment(baseline, 4, 12 and 24 weeks)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
3 期
Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese PatientsObesityNCT01570829Materia Medica Holding331
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult WomenNocturiaNCT01684800Ferring Pharmaceuticals178
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult MenNocturiaNCT01694498Ferring Pharmaceuticals183
终止
2 期
Diclofenac Patch for Treatment of Mild to Moderate Ankle SprainAnkle SprainNCT00640705Cerimon Pharmaceuticals170
已完成
3 期
Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)Acute PainSoft Tissue InjuryNCT00931866Cerimon Pharmaceuticals407